CHAM
RDHL

Clear Harbor Asset Management’s Redhill Biopharma RDHL Stock Holding History

Clear Harbor Asset Management’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-39
Closed -$323K – 272
2018
Q3 		$323K Buy
+39
New +$318K 0.07% 185

Other funds holding RDHL

6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
MC
Menta Capital San Francisco, California $236M AUM 6.6% 1-Year Est. Return

Clear Harbor Asset Management's RDHL Position: Q4 2018 in Review

Clear Harbor Asset Management sold out of Redhill Biopharma (RDHL) in Q4 2018, closing a stake of 39 shares — an estimated $323K sold.

Clear Harbor Asset Management first reported a position in RDHL in Q3 2018 and held it in 1 quarter. The position peaked at $323K in Q3 2018. 36 funds tracked by Wall St. Rank hold RDHL as of Q4 2018.

  • Clear Harbor Asset Management reported no remaining Redhill Biopharma position as of Q4 2018 after selling out during the quarter.
  • Clear Harbor Asset Management sold 39 Redhill Biopharma shares in Q4 2018, an estimated $323K.
  • Clear Harbor Asset Management first reported a position in Redhill Biopharma in Q3 2018 and held it in 1 quarter.
  • Clear Harbor Asset Management's Redhill Biopharma position peaked at $323K in Q3 2018.
  • 36 funds tracked by Wall St. Rank held Redhill Biopharma as of Q4 2018.

Based on Clear Harbor Asset Management's 13F filing for Q4 2018, filed 11 Feb 2019.